Article Text

Download PDFPDF
EP1260 Endometrium cancer and its features in our enviroment
  1. E Lopez Gonzalez,
  2. F Montero Venegas,
  3. P Barbero Duran and
  4. L Fernandez Villarrenaga
  1. Juan Ramon Jimenez Hospital, Huelva, Spain


Introduction/Background Objetive to describe the different features of the endometrial cancer in our environment in the course of five years.

Methodology Descriptive study of 170 patients who were diagnosed with endometrium cancer between 2013 and 2017. A study of different variables have been carried out; these variables include: age, presentation, diagnosis, histology, type II, LSVI; pre and post surgical, treatment given and adjuvancy, tumor grade, miometrial invasion (MI),lymphadenectomy,node involvement, reappearence and the existence or absence of surgical complications.

In the analysis of the data, the 23rd version of SPSS has been used.

Results The main reason why 85.5% of the patients attended surgery was metrorrhagia, being 50.6% diagnosed through hysteroscopy and 44.7% through endometrial aspirate. The most common found histology has been ca. Endometroid in 84.1% of the cases and lymphovascular invasion in 14.1%.

Looking at the staging of the illness, it has been concluded that 54.1% of the cases are in AI stage, 22.1% in IB stage; according to this, it has been noticed that HT+DA is the most frequent procedure, being used in 61.2% of the cases.

On the other hand, it has been detected that 53.5% of the cases presented miometrial invasion >50% and 55% of the cases were in G1. Laparoscopic surgery has been the most common choice of approach, doing lymphadenectomy in 32.9% of the cases and finding pelvic metastasis in 2.4% and para-aortic in 3.5% of the patients.

Finally, it is neccessary to remark that adjuvant treatment has not been given to 54.1% of the patients and 5.3% of recurrences in our patients was detected.

Conclusion The most usual is the endometrioid in early stages and highlighting almost a 20% of lympho-vascular space infiltration, even in those patients with an early stage in which no adjuvant treatmnent was applied.

Disclosure Nothing to disclose

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.